Hepion Pharmaceuticals Inc

Hepion Pharmaceuticals Inc Stock Forecast & Price Prediction

Live Hepion Pharmaceuticals Inc Stock (HEPA) Price
$0.73

0

Ratings

  • Buy 0
  • Hold 0
  • Sell 0
Disclaimer : Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance. This information is for educational purposes only and should not be construed as advice to buy or sell any security.

Stock Price

$0.73

P/E Ratio

-0.06

Volume Traded Today

$8,208

Dividend

Dividends not available for HEPA

52 Week High/low

7.79/0.55

Hepion Pharmaceuticals Inc Market Cap

$4.7M

๐Ÿ›‘ Alert: These ten stocks could have higher potential than $HEPA ๐Ÿ›‘

Before you buy HEPA you'll want to see this list of ten stocks that have huge potential. Want to see if HEPA made the cut? Enter your email below

HEPA Summary

Based on ratings from 0 stock analysts, the Hepion Pharmaceuticals Inc stock price is expected to increase by 4009.59% in 12 months. This is calculated by using the average 12-month stock price forecast for Hepion Pharmaceuticals Inc. The lowest target is $30 and the highest is $30. Please note analyst price targets are not guaranteed and could be missed completely.

HEPA Analyst Ratings

About 0 Wall Street analysts have assignedHEPA 0 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Hepion Pharmaceuticals Inc to sell. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on HEPA. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.

HEPA stock forecast by analyst

These are the latest 20 analyst ratings of HEPA.

Analyst/Firm

Rating

Price Target

Change

Date

Kumaraguru Raja
Brookline Capital

Hold


Downgrade

Dec 7, 2023
Kristen Kluska
Cantor Fitzgerald

Overweight

$3.5

Initiates

Feb 28, 2022

Brookline Capital

Buy


Initiates

Nov 22, 2019

HEPA Company Information

  • Company Name: Hepion Pharmaceuticals, Inc. (formerly ContraVir Pharmaceuticals, Inc.)
  • Founded: 2013
  • Headquarters: Edison, New Jersey
  • Business Focus: Development of drug therapies for chronic liver diseases in the United States
  • Key Product: Rencofilstat, a cyclophilin inhibitor
  • Clinical Trials: Rencofilstat is in Phase 2b clinical trials targeting multiple pathways of liver disease progression
  • Target Conditions: Non-alcoholic steatohepatitis (NASH), liver fibrosis, liver inflammation, and liver tumor burden
  • Antiviral Activities: Demonstrated efficacy against hepatitis B, C, D viruses, and HIV-1
  • Research Findings: Preclinical studies show reduction in liver-related complications and viral titers
HEPA
Hepion Pharmaceuticals Inc (HEPA)

When did it IPO

N/A

Staff Count

22

Country

United States

Sector/Industry

Healthcare/Biotechnology

CEO

Mr. John Patrick Brancaccio CPA

Market Cap

$4.7M

Hepion Pharmaceuticals Inc (HEPA) Financial Data

In 2023, HEPA generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that HEPA's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.

Revenue From 2020

$0

Revenue From 2021

$0

0.00 %
From Previous Year

Revenue From 2022

$0

0.00 %
From Previous Year

Revenue From 2023

$0

0.00 %
From Previous Year
  • Revenue TTM $0
  • Operating Margin TTM 0.0%
  • Gross profit TTM $0
  • Return on assets TTM -92.8%
  • Return on equity TTM -189.5%
  • Profit Margin 0.0%
  • Book Value Per Share 0.32%
  • Market capitalisation $4.7M
  • Revenue for 2021 $0
  • Revenue for 2022 $0
  • Revenue for 2023 $0
  • EPS this year (TTM) $-6.41

Hepion Pharmaceuticals Inc (HEPA) Latest News

No news data available.

...

HEPA Frequently asked questions

The highest forecasted price for HEPA is $30 from at .

The lowest forecasted price for HEPA is $30 from from

The HEPA analyst ratings consensus are 0 buy ratings, 0 hold ratings, and 0 sell ratings.